EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access

Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial

Roger Li iD, Nancy Y Villa, Xiaoqing Yu iD, Joseph O Johnson, Gustavo Borjas iD, Jasreman Dhillon iD, Carlos M Moran-Segura iD, Youngchul Kim, Natasha Francis, Denise Dorman, John J Powers iD, Wade J Sexton und 16 weitere

Nature Medicine · 2025-01 · 31 (1) · 176-188

DOI: 10.1038/s41591-024-03324-9 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Nature Medicine, online erschienen am 09.11.2024. Verfasst von Roger Li und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Roger.Li@moffitt.org. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Nivolumab, Oncolytic Virotherapy, Immunotherapy. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: U.S. Department of Defense (United States Department of Defense), NCI NIH HHS, CG Oncology, Moffitt Cancer Center, Campbell Family Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is a critical unmet need for safe and efficacious neoadjuvant treatment for cisplatin-ineligible patients with muscle-invasive bladder cancer. Here we launched a phase 1b study using the combination of intravesical cretostimogene grenadenorepvec (oncolytic serotype 5 adenovirus encoding granulocyte-macrophage colony-stimulating factor) with systemic nivolumab in cisplatin-ineligible patients with cT2-4aN0-1M0 muscle-invasive bladder cancer. The primary objective was to measure safety, and the secondary objective was to assess the anti-tumor efficacy as measured by pathologic complete response along with 1-year recurrence-free survival. No dose-limiting toxicity was encountered in 21 patients enrolled and treated. Combination treatment achieved a pathologic complete response rate of 42.1% and a 1-year recurrence-free survival rate of 70.4%. Pathologic response was associated with baseline free E2F activity and tumor mutational burden but not PD-L1 status. Although T cell infiltration was broadly induced after intravesical oncolytic immunotherapy, the formation, enlargement and maturation of tertiary lymphoid structures was specifically associated with complete response, supporting the importance of coordinated humoral and cellular immune responses. Together, these results highlight the potential of this combination regimen to enhance therapeutic efficacy in cisplatin-ineligible patients with muscle-invasive bladder cancer, warranting additional study as a neoadjuvant therapeutic option. ClinicalTrials.gov identifier: NCT04610671 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsNivolumabOncolytic VirotherapyImmunotherapyHumansMaleAgedFemaleMiddle AgedAged, 80 and overNeoplasm InvasivenessCombined Modality TherapyGranulocyte-Macrophage Colony-Stimulating Factor

Substanzen

NivolumabGranulocyte-Macrophage Colony-Stimulating Factor

Autor:innen und Institutionen

  • Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Roger.Li@moffitt.org.
  • Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Roger.Li@moffitt.org.
  • Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
  • Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
  • Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
  • Analytic Microscopy Core, H. Lee Moffitt Cancer Center, Tampa, FL, USA.

ORCID-Profile: Roger Li, Xiaoqing Yu, Gustavo Borjas, Jasreman Dhillon, Carlos M Moran-Segura, John J Powers, Jingsong Zhang, Alexander R A Anderson, Xuefeng Wang, Paulo C Rodriguez, James J Mulé, Jose R Conejo-Garcia

Förderung

  • U.S. Department of Defense (United States Department of Defense)
  • NCI NIH HHS
  • CG Oncology, Moffitt Cancer Center, Campbell Family Foundation

Zitieren

APA

Li, R., Villa, N. Y., Yu, X., Johnson, J. O., Borjas, G., Dhillon, J., Moran-Segura, C. M., Kim, Y., Francis, N., Dorman, D., Powers, J. J., Sexton, W. J., Spiess, P. E., Poch, M. A., Zemp, L., Gilbert, S. M., Zhang, J., Pow-Sang, J. M., Anderson, A. R. A., …, & Conejo-Garcia, J. R. (2025). Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial. Nature Medicine, 31(1), 176-188. https://doi.org/10.1038/s41591-024-03324-9

Vancouver

Li R, Villa NY, Yu X, Johnson JO, Borjas G, Dhillon J, et al. Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial. Nature Medicine. 2025;31(1):176-188. doi:10.1038/s41591-024-03324-9

BibTeX
@article{Li2025,
  author = {Li, Roger and Villa, Nancy Y and Yu, Xiaoqing and Johnson, Joseph O and Borjas, Gustavo and Dhillon, Jasreman and Moran-Segura, Carlos M and Kim, Youngchul and Francis, Natasha and Dorman, Denise and Powers, John J and Sexton, Wade J and Spiess, Philippe E and Poch, Michael A and Zemp, Logan and Gilbert, Scott M and Zhang, Jingsong and Pow-Sang, Julio M and Anderson, Alexander R A and Li, Tingyi and Wang, Xuefeng and Grass, G Daniel and Burke, James M and Dinney, Colin P N and Rodriguez, Paulo C and Jain, Rohit K and Mulé, James J and Conejo-Garcia, Jose R},
  title = {Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial},
  journal = {Nature Medicine},
  year = {2025},
  volume = {31},
  number = {1},
  pages = {176--188},
  doi = {10.1038/s41591-024-03324-9}
}
Kostenlos starten →